Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioNTech SE

https://biontech.de/

Latest From BioNTech SE

Finance Watch: Biopharma Public Offerings Fell In Q4, But Activity Is Booming In Q1

Public Company Edition: Fourth quarter 2023 fundraising fell 25.1% from Q4 2022, including a 24.2% drop in follow-on dollars, but recent activity has been robust, including $300m and $350m offerings by 4DMT and Autolus. Also, BMS sold $13bn in notes to fund Karuna and RayzeBio deals.

Financing Business Strategies

Autolus Gets Cash From BioNTech, Which Gets Manufacturing And Options

Deal Snapshot: BioNTech and Autolus partner up in a CAR-T deal that will give Autolus more capital ahead of the potential launch of obecabtagene autoleucel.

Deals Financing

Finance Watch: Ascendis Spins Out Ophthalmology Firm Eyconis With $150m

Private Company Edition: Publicly held Ascendis outsourced its preclinical AMD program to private Eyconis. Also, Innovation Endeavors revealed a new $630m VC fund and Mirae raised $50m for its first life science fund, while Accent, Comanche and Tr1X each brought in $75m rounds.

Financing Innovation

Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering

Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.

Scrip Asks Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Other Names / Subsidiaries
    • BioNTech US Inc.
    • Biopharmaceutical New Technologies AG
    • Neon Therapeutics, Inc.
    • BioNTech AG
UsernamePublicRestriction

Register